We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Neovacs | EU:ALNEV | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.0122 | 0.0122 | 0.0154 | 0.00 | 01:00:00 |
From Jul 2019 to Jul 2024
PRESS RELEASE PRESS RELEASE PRESS RELEASE
2019 Financial Calendar
Paris, April 5, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases publishes an updated 2019 financial calendar today.
Financial announcements will be published before the market opening. The expected dates are preliminary so may be subject to change.
The 2018 full annual financial report will be published online at www.neovacs.com no later than April 30, 2019
About NeovacsListed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
| NéovacsCorporate Communication& Investor RelationsCharlène Masson+33 1 53 10 93 00cmasson@neovacs.com | Press Relations – NewCapAnnie-Florence Loyer+33 (0)6 88 20 35 59 +33 (0)1 44 71 00 12afloyer@newcap.frLéa JacquinTel : +33(0)1 44 71 20 41ljacquin@newcap.fr | Orphéon FinanceFinancial Communication and Investor RelationsJames Palmer+33 7 60 92 77 74j.palmer@orpheonfinance.com |
Attachment
1 Year Neovacs Chart |
1 Month Neovacs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
